|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0023467,
umls-concept:C0032520,
umls-concept:C0035647,
umls-concept:C0239307,
umls-concept:C0392762,
umls-concept:C0694898,
umls-concept:C1510438,
umls-concept:C1511791,
umls-concept:C1514983,
umls-concept:C2349975,
umls-concept:C2603343
|
|
pubmed:issue |
31
|
|
pubmed:dateCreated |
2009-10-30
|
|
pubmed:abstractText |
Risk stratification in acute myeloid leukemia (AML) is currently based on pretreatment characteristics. It remains to be established whether relapse risk can be better predicted through assessment of minimal residual disease (MRD). One proposed marker is the Wilms tumor gene WT1, which is overexpressed in most patients with AML, thus providing a putative target for immunotherapy, although in the absence of a standardized assay, its utility for MRD monitoring remains controversial.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:CilloniDanielaD,
pubmed-author:DalySarahS,
pubmed-author:FavaMilenaM,
pubmed-author:GottardiEnricoE,
pubmed-author:GrimwadeDavidD,
pubmed-author:HermitteFabienneF,
pubmed-author:HillsRobert KRK,
pubmed-author:IzzoBarbaraB,
pubmed-author:JansenJoop HJH,
pubmed-author:JovanovicJelena VJV,
pubmed-author:NomdedeuJosepJ,
pubmed-author:OmmenHansH,
pubmed-author:PreudhommeClaudeC,
pubmed-author:RennevilleAlineA,
pubmed-author:SaglioGiuseppeG,
pubmed-author:SchnittgerSusanneS,
pubmed-author:WeissTamaraT,
pubmed-author:van der HeijdenAdrianA,
pubmed-author:van der ReijdenBert ABA,
pubmed-author:van der VeldenVincent H JVH
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5195-201
|
|
pubmed:meshHeading |
pubmed-meshheading:19752335-Adolescent,
pubmed-meshheading:19752335-Adult,
pubmed-meshheading:19752335-Aged,
pubmed-meshheading:19752335-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19752335-Child,
pubmed-meshheading:19752335-Child, Preschool,
pubmed-meshheading:19752335-DNA Mutational Analysis,
pubmed-meshheading:19752335-Gene Expression,
pubmed-meshheading:19752335-Genes, Wilms Tumor,
pubmed-meshheading:19752335-Humans,
pubmed-meshheading:19752335-Leukemia, Myeloid, Acute,
pubmed-meshheading:19752335-Middle Aged,
pubmed-meshheading:19752335-Neoplasm, Residual,
pubmed-meshheading:19752335-Prognosis,
pubmed-meshheading:19752335-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:19752335-Risk Factors,
pubmed-meshheading:19752335-Tumor Markers, Biological,
pubmed-meshheading:19752335-Young Adult
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
|
|
pubmed:affiliation |
Department of Clinical and Biological Sciences, University of Turin, Turin.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
